Abstract
BackgroundIn recent years, the FDA has approved engineered autologous T cell therapies with remarkable efficacy against hematological cancers. In addition, non-engineered tumor infiltrating lymphocyte (TIL) therapies have shown unprecedented benefit...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
